telos rx review: "cancel anytime, no penalties" and a clawback in the terms

Its product pages say so and its terms describe otherwise. Under "Multi-month plan commitments and early cancellation", the terms state that the discounted per-month rate "is contingent on completing the full committed term", that canceling early forfeits the multi-month discount, and that the months already received "will be re-rated to the per-month price of the shortest plan term that covers the period you were actually enrolled" — with telos rx authorized to "charge the difference… as a one-time adjustment at the time of cancellation." Its own example: enroll for twelve months, cancel after three, and those three months are re-priced at the three-month rate. A one-month plan has no multi-month discount to forfeit, so this applies to the longer terms — which are the ones the advertised prices come from.

For the one product where it publishes a ladder, oral tirzepatide: $199 for the first month on the one-month plan, $129 on the three-month, $99 on the six-month and $49 on the twelve-month. For its injectable tirzepatide, semaglutide, microdosed tirzepatide and NAD+ nasal spray, it publishes only a pair of numbers — for example "As low as $399 $139 per month" — and never says what the larger figure is or which plan produces the smaller one. The selector that would answer that’s behind "Start your intake", so this review prices the product it can and says so about the rest.

Twelve months at the one-month plan’s $199 is $2,388, and that’s arithmetic on telos rx’s own figure rather than a price it quotes. That $199 is itself a first month carrying $30 off, so a real year costs more than the multiplication suggests. On the three-, six- and twelve-month plans only the first month carries a number — $129, $99 and $49 — and telos rx publishes no total for any of those terms.

Because a walk-away price has to be a number the company publishes, not one we infer. telos rx's four injectable and nasal products each show "As low as $X per month" beside a larger unlabeled figure. The larger number may well be the one-month rate — but the site never says that, and putting a guess in the walk-away column is the one failure this site can’t afford. Oral tirzepatide is filed because its plan chooser states four terms with four prices, so the shortest commitment is a published fact.

No, and the search that answers this is worth showing because it nearly says otherwise. FDA's warning-letter index returns exactly one letter for the query "telos": it’s addressed to Telos Trading Limited dba Alwinshop, a different company with a different business. Matching on the shared word would be an accusation against the wrong party. A "sprout" query run in the same pass returned Sprout Health's real letter, which is what makes this zero evidence rather than a broken search.

It doesn’t say. Every product page carries "503A/503B pharmacy network" — the category, stated twice over, with no pharmacy name, address or license number. It’s worth noting that 503A and 503B are different things: a 503A pharmacy compounds for an individual patient against a prescription, and a 503B outsourcing facility manufactures in batches and registers with FDA. A given preparation comes from one or the other, so naming both describes a network rather than the source of your medication.